Isofol Medical AB (OSTO:ISOFOL) EV-to-FCF: -2.68 (As of Jul. 04, 2026)


OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.81
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB EV-to-FCF?

Isofol Medical AB OSTO:ISOFOL +5.88% 30 EV-to-FCF is -2.68 as of Jul. 04, 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 332 Biotechnology companies, Isofol Medical AB ranks worse than 301204.52% on this metric.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Isofol Medical AB's Enterprise Value is kr148.86 Mil. Isofol Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-55.58 Mil. Therefore, Isofol Medical AB's EV-to-FCF for today is -2.68.

The historical rank and industry rank for Isofol Medical AB's EV-to-FCF or its related term are showing as below:

OSTO:ISOFOL' s EV-to-FCF Range Over the Past 10 Years
Min: -15.11   Med: -3.75   Max: 2.88
Current: -2.08

During the past 11 years, the highest EV-to-FCF of Isofol Medical AB was 2.88. The lowest was -15.11. And the median was -3.75.

OSTO:ISOFOL's EV-to-FCF is ranked worse than
100% of 332 companies
in the Biotechnology industry
Industry Median: 16.26 vs OSTO:ISOFOL: -2.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-04), Isofol Medical AB's stock price is kr0.81. Isofol Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.240. Therefore, Isofol Medical AB's PE Ratio (TTM) for today is At Loss.


Isofol Medical AB  (OSTO:ISOFOL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Isofol Medical AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.81/-0.240
=At Loss

Isofol Medical AB's share price for today is kr0.81.
Isofol Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Isofol Medical AB EV-to-FCF Related Terms


Isofol Medical AB EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB EV-to-FCF Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.92 0.37 0.39 -6.25 -1.50

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.63 -2.03 -1.76 -1.50 -1.29

OSTO:ISOFOL vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Isofol Medical AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Isofol Medical AB EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Isofol Medical AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Isofol Medical AB's EV-to-FCF falls into.


OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB EV-to-FCF Calculation

Isofol Medical AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=148.857/-55.583
=-2.68

Isofol Medical AB's current Enterprise Value is kr148.86 Mil.
Isofol Medical AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-55.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -2.68 mean?
Isofol Medical AB (OSTO:ISOFOL) has a EV-to-FCF of -2.68 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Isofol Medical AB and its competitors. According to the industry distribution chart, Isofol Medical AB ranks #999999 out of 332 companies in the Biotechnology industry.
Is Isofol Medical AB's EV-to-FCF too high?
Isofol Medical AB's current EV-to-FCF is -2.68. Based on the distribution chart, Isofol Medical AB ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Isofol Medical AB ranks #999999 out of 332 companies for EV-to-FCF. This places Isofol Medical AB in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Isofol Medical AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Isofol Medical AB's current EV-to-FCF is -2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current EV-to-FCF of -2.68. The current EV-to-FCF is -2.68. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current EV-to-FCF is -2.68 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.81
Price